{"id":{"repo_id":"msu","oai_identifier":"oai:d.lib.msu.edu:etd_589"},"canonical_url":"https://search.ndltd.org/etd/msu/oai:d.lib.msu.edu:etd_589","repository":{"repo_id":"msu","name":"Michigan State University","base_url":"https://d.lib.msu.edu/oai"},"display":{"title":"Mechanistic and functional studies of zinc (II) activation of C-peptide and its effect on red blood cell metabolism","abstract":"ABSTRACT MECHANISTIC AND FUNCTIONAL STUDIES OF ZINC (II) ACTIVATION OF C-PEPTIDE AND ITS EFFECT ON RED BLOOD CELL METABOLISM By Wathsala Medawala C-peptide, a 31 amino acid peptide co-secreted with insulin from &beta;-cells in the pancreas, has long been considered a by-product of insulin synthesis. Later it was discovered that C-peptide could ameliorate diabetic complications such as neuropathy, nephropathy, retinopathy and microvascular disease. However, the molecular mechanism behind the effects of C-peptide is not yet completely understood. The effect of C-peptide on the microcirculation is important, because problems in the circulation have been linked to other diabetic complications. C-peptide improves the microcirculation by increasing endothelial-derived nitric oxide (NO), red blood cell (RBC) deformability and Na<super>+</super>/K<super>+</super>-ATPase activity. C-peptide increases glucose utilization and ATP release from RBCs and endothelial cells. ATP is a stimulus for the production of endothelial-derived NO, which is a known vasodilator. Therefore, the C-peptide mediated increase in RBC-derived ATP release can lead to the improvement of blood flow.C-peptide alone did not increase RBC-derived ATP release. The presence of a metal ion such as Zn<super>2+</super> was needed to elicit this response. However, the role of Zn<super>2+</super> in C-peptide activity is not fully understood. A fluorescence based study was used to investigate the binding of Zn<super>2+</super> to C-peptide. Results indicate that C-peptide binds one Zn<super>2+</super> ion and has a binding constant of 1.02 x 10<super>7</super> M<super>-1</super> with Zn<super>2+</super> at pH 5.5, which is the pH inside a mature &beta;-cell granule. At physiological pH of 7.4, C-peptide binds with two Zn<super>2+</super> ions and has a binding constant of 7.99 x 10<super>6</super> M<super>-1</super>. This indicates that C-peptide may bind with Zn<super>2+</super> inside the &beta;-cell granule and release Zn<super>2+</super> upon entering the blood stream. Circular dichroism studies suggest that a 1:1 Zn<super>2+</super> to C-peptide ratio elicits a decrease in the randomness of the peptide chain, which is lost at higher Zn<super>2+</super> to C-peptide ratios.Five single amino acid peptide mutants of C-peptide were used to study the effect of the acidic amino acid residues on Zn<super>2+</super> binding. Substitution of glutamate residues at positions 27, 11 and 3 decreased the Zn<super>2+</super> binding to C-peptide by ~50%, agreeing with the activity of these mutants in other bio-assays. Several studies have indicated the necessity of insulin for C-peptide activity. The Zn<super>2+</super> that available with insulin hexamers may be responsible for activation of C-peptide. Using a RBC-derived ATP assay, it was shown that Zn<super>2+</super> added in the form of Zn-insulin activates C-peptide, as observed by the increase in ATP release. The C-peptide interaction with RBCs was studied using an ELISA. Zn<super>2+</super>-activated C-peptide bound to RBCs in a dose dependent manner, 2 pmol of Zn<super>2+</super>-activated C-peptide binding to 1 mL of 7% red blood cell sample at saturation (~1500 molecules/ cell). The interaction did not change significantly even in the absence of Zn<super>2+</super>. However, Zn<super>2+</super> uptake in RBCs was observed only in the presence of C-peptide, indicating a possible role for C-peptide as a Zn<super>2+</super> carrier. One argument against C-peptide being a potential medication is that patients with type 2 diabetes develop the complications of the disease despite having circulating C-peptide. Red blood cells incubated in high glucose (>10 mM), showed lower interaction with Zn<super>2+</super>-activated C-peptide and lower ATP release, showing that patients with uncontrolled blood glucose levels might show resistance to the action of the peptide. Also, the exposure of Zn<super>2+</super>-activated C-peptide to serum albumin and mM levels of other cations and anions decreases its activity. Taken together, the work presented in this dissertation explains the role of Zn<super>2+</super> in C-peptide action and how reproducible results may be obtained in C-peptide clinical trials.","abstract_html":"ABSTRACT MECHANISTIC AND FUNCTIONAL STUDIES OF ZINC (II) ACTIVATION OF C-PEPTIDE AND ITS EFFECT ON RED BLOOD CELL METABOLISM By Wathsala Medawala C-peptide, a 31 amino acid peptide co-secreted with insulin from &amp;beta;-cells in the pancreas, has long been considered a by-product of insulin synthesis. Later it was discovered that C-peptide could ameliorate diabetic complications such as neuropathy, nephropathy, retinopathy and microvascular disease. However, the molecular mechanism behind the effects of C-peptide is not yet completely understood. The effect of C-peptide on the microcirculation is important, because problems in the circulation have been linked to other diabetic complications. C-peptide improves the microcirculation by increasing endothelial-derived nitric oxide (NO), red blood cell (RBC) deformability and Na&lt;super&gt;+&lt;/super&gt;/K&lt;super&gt;+&lt;/super&gt;-ATPase activity. C-peptide increases glucose utilization and ATP release from RBCs and endothelial cells. ATP is a stimulus for the production of endothelial-derived NO, which is a known vasodilator. Therefore, the C-peptide mediated increase in RBC-derived ATP release can lead to the improvement of blood flow.C-peptide alone did not increase RBC-derived ATP release. The presence of a metal ion such as Zn&lt;super&gt;2+&lt;/super&gt; was needed to elicit this response. However, the role of Zn&lt;super&gt;2+&lt;/super&gt; in C-peptide activity is not fully understood. A fluorescence based study was used to investigate the binding of Zn&lt;super&gt;2+&lt;/super&gt; to C-peptide. Results indicate that C-peptide binds one Zn&lt;super&gt;2+&lt;/super&gt; ion and has a binding constant of 1.02 x 10&lt;super&gt;7&lt;/super&gt; M&lt;super&gt;-1&lt;/super&gt; with Zn&lt;super&gt;2+&lt;/super&gt; at pH 5.5, which is the pH inside a mature &amp;beta;-cell granule. At physiological pH of 7.4, C-peptide binds with two Zn&lt;super&gt;2+&lt;/super&gt; ions and has a binding constant of 7.99 x 10&lt;super&gt;6&lt;/super&gt; M&lt;super&gt;-1&lt;/super&gt;. This indicates that C-peptide may bind with Zn&lt;super&gt;2+&lt;/super&gt; inside the &amp;beta;-cell granule and release Zn&lt;super&gt;2+&lt;/super&gt; upon entering the blood stream. Circular dichroism studies suggest that a 1:1 Zn&lt;super&gt;2+&lt;/super&gt; to C-peptide ratio elicits a decrease in the randomness of the peptide chain, which is lost at higher Zn&lt;super&gt;2+&lt;/super&gt; to C-peptide ratios.Five single amino acid peptide mutants of C-peptide were used to study the effect of the acidic amino acid residues on Zn&lt;super&gt;2+&lt;/super&gt; binding. Substitution of glutamate residues at positions 27, 11 and 3 decreased the Zn&lt;super&gt;2+&lt;/super&gt; binding to C-peptide by ~50%, agreeing with the activity of these mutants in other bio-assays. Several studies have indicated the necessity of insulin for C-peptide activity. The Zn&lt;super&gt;2+&lt;/super&gt; that available with insulin hexamers may be responsible for activation of C-peptide. Using a RBC-derived ATP assay, it was shown that Zn&lt;super&gt;2+&lt;/super&gt; added in the form of Zn-insulin activates C-peptide, as observed by the increase in ATP release. The C-peptide interaction with RBCs was studied using an ELISA. Zn&lt;super&gt;2+&lt;/super&gt;-activated C-peptide bound to RBCs in a dose dependent manner, 2 pmol of Zn&lt;super&gt;2+&lt;/super&gt;-activated C-peptide binding to 1 mL of 7% red blood cell sample at saturation (~1500 molecules/ cell). The interaction did not change significantly even in the absence of Zn&lt;super&gt;2+&lt;/super&gt;. However, Zn&lt;super&gt;2+&lt;/super&gt; uptake in RBCs was observed only in the presence of C-peptide, indicating a possible role for C-peptide as a Zn&lt;super&gt;2+&lt;/super&gt; carrier. One argument against C-peptide being a potential medication is that patients with type 2 diabetes develop the complications of the disease despite having circulating C-peptide. Red blood cells incubated in high glucose (&gt;10 mM), showed lower interaction with Zn&lt;super&gt;2+&lt;/super&gt;-activated C-peptide and lower ATP release, showing that patients with uncontrolled blood glucose levels might show resistance to the action of the peptide. Also, the exposure of Zn&lt;super&gt;2+&lt;/super&gt;-activated C-peptide to serum albumin and mM levels of other cations and anions decreases its activity. Taken together, the work presented in this dissertation explains the role of Zn&lt;super&gt;2+&lt;/super&gt; in C-peptide action and how reproducible results may be obtained in C-peptide clinical trials.","abstract_has_math":false,"creators":["Medawala, Wathsala"],"institution":null,"degree_name":null,"degree_level":null,"degree_discipline":null,"degree_department":null,"school":null,"contributors":["Spence, Dana M.","Reid, Gavin","Jones, Daniel","Smith, Mitch"],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2011,"date_issued":"2011","date_published":"2011","updated_at":"2026-11-18T19:00:11Z","subjects":["C-peptide","Cell metabolism","Diabetes--Research"],"languages":["English"],"rights":["In Copyright"],"rights_urls":[],"identifier_entries":[{"key":"dc:identifier","label":"Identifier","values":["etd:589","isbn:9781124858876","isbn:1124858873","oclc:931743348","umi:3469659","local:Medawala_grad.msu_0128D_10734"],"render_values":[{"text":"etd:589","href":null,"code":true},{"text":"isbn:9781124858876","href":null,"code":true},{"text":"isbn:1124858873","href":null,"code":true},{"text":"oclc:931743348","href":null,"code":true},{"text":"umi:3469659","href":null,"code":true},{"text":"local:Medawala_grad.msu_0128D_10734","href":null,"code":true}]}],"person_identifier_entries":[]},"links":{"outbound_url":"https://doi.org/doi:10.25335/205d-vf02","outbound_label":"DOI","outbound_source":"dc:identifier","record_url":"https://doi.org/doi:10.25335/205d-vf02","record_label":"Repository record","record_kind":"doi","record_source":"dc:identifier","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://d.lib.msu.edu/oai?verb=GetRecord&metadataPrefix=oai_dc&identifier=oai%3Ad.lib.msu.edu%3Aetd_589","prefix":"oai_dc"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["Spence, Dana M.","Reid, Gavin","Jones, Daniel","Smith, Mitch"]},{"key":"dc:creator","label":"Author","values":["Medawala, Wathsala"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2011"]},{"key":"dc:relation","label":"Dc Relation","values":["Electronic Theses & Dissertations"]},{"key":"dc:type","label":"Dc Type","values":["Text","Theses"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["C-peptide","Cell metabolism","Diabetes--Research"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language","label":"Dc Language","values":["English"]},{"key":"dc:rights","label":"Dc Rights","values":["In Copyright"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["etd:589","isbn:9781124858876","isbn:1124858873","oclc:931743348","umi:3469659","local:Medawala_grad.msu_0128D_10734","https://doi.org/doi:10.25335/205d-vf02"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["ABSTRACT MECHANISTIC AND FUNCTIONAL STUDIES OF ZINC (II) ACTIVATION OF C-PEPTIDE AND ITS EFFECT ON RED BLOOD CELL METABOLISM By Wathsala Medawala C-peptide, a 31 amino acid peptide co-secreted with insulin from &beta;-cells in the pancreas, has long been considered a by-product of insulin synthesis. Later it was discovered that C-peptide could ameliorate diabetic complications such as neuropathy, nephropathy, retinopathy and microvascular disease. However, the molecular mechanism behind the effects of C-peptide is not yet completely understood. The effect of C-peptide on the microcirculation is important, because problems in the circulation have been linked to other diabetic complications. C-peptide improves the microcirculation by increasing endothelial-derived nitric oxide (NO), red blood cell (RBC) deformability and Na<super>+</super>/K<super>+</super>-ATPase activity. C-peptide increases glucose utilization and ATP release from RBCs and endothelial cells. ATP is a stimulus for the production of endothelial-derived NO, which is a known vasodilator. Therefore, the C-peptide mediated increase in RBC-derived ATP release can lead to the improvement of blood flow.C-peptide alone did not increase RBC-derived ATP release. The presence of a metal ion such as Zn<super>2+</super> was needed to elicit this response. However, the role of Zn<super>2+</super> in C-peptide activity is not fully understood. A fluorescence based study was used to investigate the binding of Zn<super>2+</super> to C-peptide. Results indicate that C-peptide binds one Zn<super>2+</super> ion and has a binding constant of 1.02 x 10<super>7</super> M<super>-1</super> with Zn<super>2+</super> at pH 5.5, which is the pH inside a mature &beta;-cell granule. At physiological pH of 7.4, C-peptide binds with two Zn<super>2+</super> ions and has a binding constant of 7.99 x 10<super>6</super> M<super>-1</super>. This indicates that C-peptide may bind with Zn<super>2+</super> inside the &beta;-cell granule and release Zn<super>2+</super> upon entering the blood stream. Circular dichroism studies suggest that a 1:1 Zn<super>2+</super> to C-peptide ratio elicits a decrease in the randomness of the peptide chain, which is lost at higher Zn<super>2+</super> to C-peptide ratios.Five single amino acid peptide mutants of C-peptide were used to study the effect of the acidic amino acid residues on Zn<super>2+</super> binding. Substitution of glutamate residues at positions 27, 11 and 3 decreased the Zn<super>2+</super> binding to C-peptide by ~50%, agreeing with the activity of these mutants in other bio-assays. Several studies have indicated the necessity of insulin for C-peptide activity. The Zn<super>2+</super> that available with insulin hexamers may be responsible for activation of C-peptide. Using a RBC-derived ATP assay, it was shown that Zn<super>2+</super> added in the form of Zn-insulin activates C-peptide, as observed by the increase in ATP release. The C-peptide interaction with RBCs was studied using an ELISA. Zn<super>2+</super>-activated C-peptide bound to RBCs in a dose dependent manner, 2 pmol of Zn<super>2+</super>-activated C-peptide binding to 1 mL of 7% red blood cell sample at saturation (~1500 molecules/ cell). The interaction did not change significantly even in the absence of Zn<super>2+</super>. However, Zn<super>2+</super> uptake in RBCs was observed only in the presence of C-peptide, indicating a possible role for C-peptide as a Zn<super>2+</super> carrier. One argument against C-peptide being a potential medication is that patients with type 2 diabetes develop the complications of the disease despite having circulating C-peptide. Red blood cells incubated in high glucose (>10 mM), showed lower interaction with Zn<super>2+</super>-activated C-peptide and lower ATP release, showing that patients with uncontrolled blood glucose levels might show resistance to the action of the peptide. Also, the exposure of Zn<super>2+</super>-activated C-peptide to serum albumin and mM levels of other cations and anions decreases its activity. Taken together, the work presented in this dissertation explains the role of Zn<super>2+</super> in C-peptide action and how reproducible results may be obtained in C-peptide clinical trials.","Thesis (Ph. D.)--Michigan State University, Department of Chemistry, 2011","Includes bibliographical references"]},{"key":"dc:format","label":"Dc Format","values":["209 pages","application/pdf"]},{"key":"dc:title","label":"Title","values":["Mechanistic and functional studies of zinc (II) activation of C-peptide and its effect on red blood cell metabolism"]}]}],"canonical_facts":{"dc:contributor":["Spence, Dana M.","Reid, Gavin","Jones, Daniel","Smith, Mitch"],"dc:creator":["Medawala, Wathsala"],"dc:date":["2011"],"dc:description":["ABSTRACT MECHANISTIC AND FUNCTIONAL STUDIES OF ZINC (II) ACTIVATION OF C-PEPTIDE AND ITS EFFECT ON RED BLOOD CELL METABOLISM By Wathsala Medawala C-peptide, a 31 amino acid peptide co-secreted with insulin from &beta;-cells in the pancreas, has long been considered a by-product of insulin synthesis. Later it was discovered that C-peptide could ameliorate diabetic complications such as neuropathy, nephropathy, retinopathy and microvascular disease. However, the molecular mechanism behind the effects of C-peptide is not yet completely understood. The effect of C-peptide on the microcirculation is important, because problems in the circulation have been linked to other diabetic complications. C-peptide improves the microcirculation by increasing endothelial-derived nitric oxide (NO), red blood cell (RBC) deformability and Na<super>+</super>/K<super>+</super>-ATPase activity. C-peptide increases glucose utilization and ATP release from RBCs and endothelial cells. ATP is a stimulus for the production of endothelial-derived NO, which is a known vasodilator. Therefore, the C-peptide mediated increase in RBC-derived ATP release can lead to the improvement of blood flow.C-peptide alone did not increase RBC-derived ATP release. The presence of a metal ion such as Zn<super>2+</super> was needed to elicit this response. However, the role of Zn<super>2+</super> in C-peptide activity is not fully understood. A fluorescence based study was used to investigate the binding of Zn<super>2+</super> to C-peptide. Results indicate that C-peptide binds one Zn<super>2+</super> ion and has a binding constant of 1.02 x 10<super>7</super> M<super>-1</super> with Zn<super>2+</super> at pH 5.5, which is the pH inside a mature &beta;-cell granule. At physiological pH of 7.4, C-peptide binds with two Zn<super>2+</super> ions and has a binding constant of 7.99 x 10<super>6</super> M<super>-1</super>. This indicates that C-peptide may bind with Zn<super>2+</super> inside the &beta;-cell granule and release Zn<super>2+</super> upon entering the blood stream. Circular dichroism studies suggest that a 1:1 Zn<super>2+</super> to C-peptide ratio elicits a decrease in the randomness of the peptide chain, which is lost at higher Zn<super>2+</super> to C-peptide ratios.Five single amino acid peptide mutants of C-peptide were used to study the effect of the acidic amino acid residues on Zn<super>2+</super> binding. Substitution of glutamate residues at positions 27, 11 and 3 decreased the Zn<super>2+</super> binding to C-peptide by ~50%, agreeing with the activity of these mutants in other bio-assays. Several studies have indicated the necessity of insulin for C-peptide activity. The Zn<super>2+</super> that available with insulin hexamers may be responsible for activation of C-peptide. Using a RBC-derived ATP assay, it was shown that Zn<super>2+</super> added in the form of Zn-insulin activates C-peptide, as observed by the increase in ATP release. The C-peptide interaction with RBCs was studied using an ELISA. Zn<super>2+</super>-activated C-peptide bound to RBCs in a dose dependent manner, 2 pmol of Zn<super>2+</super>-activated C-peptide binding to 1 mL of 7% red blood cell sample at saturation (~1500 molecules/ cell). The interaction did not change significantly even in the absence of Zn<super>2+</super>. However, Zn<super>2+</super> uptake in RBCs was observed only in the presence of C-peptide, indicating a possible role for C-peptide as a Zn<super>2+</super> carrier. One argument against C-peptide being a potential medication is that patients with type 2 diabetes develop the complications of the disease despite having circulating C-peptide. Red blood cells incubated in high glucose (>10 mM), showed lower interaction with Zn<super>2+</super>-activated C-peptide and lower ATP release, showing that patients with uncontrolled blood glucose levels might show resistance to the action of the peptide. Also, the exposure of Zn<super>2+</super>-activated C-peptide to serum albumin and mM levels of other cations and anions decreases its activity. Taken together, the work presented in this dissertation explains the role of Zn<super>2+</super> in C-peptide action and how reproducible results may be obtained in C-peptide clinical trials.","Thesis (Ph. D.)--Michigan State University, Department of Chemistry, 2011","Includes bibliographical references"],"dc:format":["209 pages","application/pdf"],"dc:identifier":["etd:589","isbn:9781124858876","isbn:1124858873","oclc:931743348","umi:3469659","local:Medawala_grad.msu_0128D_10734","https://doi.org/doi:10.25335/205d-vf02"],"dc:language":["English"],"dc:relation":["Electronic Theses & Dissertations"],"dc:rights":["In Copyright"],"dc:subject":["C-peptide","Cell metabolism","Diabetes--Research"],"dc:title":["Mechanistic and functional studies of zinc (II) activation of C-peptide and its effect on red blood cell metabolism"],"dc:type":["Text","Theses"]},"updated_at":"2026-11-18T19:00:11Z"}